在与阿尔茨海默氏病相关的氧化应激依赖大脑内皮屏障功能障碍中改变铜运输
Md Selim Hossain1, Archita Das2, Ashiq M Rafiq3
1Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912.
Vascular pharmacology
|September 24, 2024
概括
在阿尔茨海默氏症 (AD) 中,铜运输蛋白质的调节失调,导致大脑中的铜量增加. 这项研究表明,通过CTR1吸收铜有助于AD中β-粉样蛋白诱导的血脑屏障功能障碍.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 涉及氧化应激和血脑屏障 (BBB) 破坏,与β-粉样蛋白 (Aβ) 斑块有关.
- 铜 (Cu) 失调与阿尔茨海默病有关,但其在大脑内皮屏障功能中的作用尚不清楚.
研究的目的:
- 在AD小鼠模型中研究铜运输蛋白表达.
- 确定这些蛋白质在Aβ42诱导的大脑内皮壁障碍功能障碍中的作用.
主要方法:
- 在AD小鼠模型和Aβ42治疗的人类大脑微血管内皮细胞 (hBMECs) 中检查了铜运输蛋白表达.
- 使用ICP-MS.测量铜含量.
- 评估了Aβ42诱导的活性氧物种 (ROS) 生产,屏障功能 (超内皮电阻) 和CDH5酸化.
主要成果:
- 在AD模型和Aβ42处理的hBMEC中,CTR1 (铜吸收) 被上调,ATP7A (铜出口) 被下调.
- 在5xFAD AD小鼠中,海马铜水平升高.
- 由Aβ42诱导的ROS,屏障功能障碍和CDH5酸化通过铜化或CTR1敲击降低.
结论:
- 不调节的铜运输蛋白可能会导致AD大脑中的细胞内铜积累.
- Aβ42通过CTR1-铜依赖途径促进ROS依赖的BBB功能障碍和CDH5酸化.
- 铜运输蛋白在AD中与氧化应激相关的BBB完整性损失中至关重要.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.贝塔-氨基胺是一种β-氨基胺血液大脑屏障 血液大脑屏障大脑的微血管内皮细胞.铜铜 铜铜 铜铜在Cu运输蛋白质中.氧化应激是一种氧化应激.有反应性氧物种的反应性氧物种.更多相关视频
10:36In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
Published on: June 20, 2017
8.5K
07:22Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
Published on: November 8, 2017
9.9K
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
The Blood-brain Barrier
47.0K
Overview
47.0K
